vs

Side-by-side financial comparison of Clipper Realty Inc. (CLPR) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

Clipper Realty Inc. is the larger business by last-quarter revenue ($37.1M vs $27.6M, roughly 1.3× Zymeworks Inc.). Clipper Realty Inc. runs the higher net margin — -30.4% vs -71.0%, a 40.6% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs -2.6%).

Clipper Equity LLC is a partnership led by David Bistricer and Sam Levinson. The firm owns more than 60 buildings, with thousands of residential units, in New York and New Jersey. The partnership are known for their attempted purchase of the Starrett City housing complex in Brooklyn, New York, for $1.3 billion on February 8, 2007, in one of the largest real estate transactions in history. New York's Mayor Michael Bloomberg expressed concerns over the new landlord's history of building violati...

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

CLPR vs ZYME — Head-to-Head

Bigger by revenue
CLPR
CLPR
1.3× larger
CLPR
$37.1M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+75.2% gap
ZYME
72.6%
-2.6%
CLPR
Higher net margin
CLPR
CLPR
40.6% more per $
CLPR
-30.4%
-71.0%
ZYME

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CLPR
CLPR
ZYME
ZYME
Revenue
$37.1M
$27.6M
Net Profit
$-11.3M
$-19.6M
Gross Margin
-5.2%
Operating Margin
21.8%
-80.1%
Net Margin
-30.4%
-71.0%
Revenue YoY
-2.6%
72.6%
Net Profit YoY
-938.6%
34.3%
EPS (diluted)
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLPR
CLPR
ZYME
ZYME
Q4 25
$37.1M
Q3 25
$37.7M
$27.6M
Q2 25
$39.0M
$48.7M
Q1 25
$39.4M
$27.1M
Q4 24
$38.0M
$31.0M
Q3 24
$37.6M
$16.0M
Q2 24
$37.3M
$19.2M
Q1 24
$35.8M
$10.0M
Net Profit
CLPR
CLPR
ZYME
ZYME
Q4 25
$-11.3M
Q3 25
$-4.6M
$-19.6M
Q2 25
$-1.4M
$2.3M
Q1 25
$-35.1M
$-22.6M
Q4 24
$-1.1M
$-23.5M
Q3 24
$-1.1M
$-29.9M
Q2 24
$-1.7M
$-37.7M
Q1 24
$-2.7M
$-31.7M
Gross Margin
CLPR
CLPR
ZYME
ZYME
Q4 25
-5.2%
Q3 25
23.6%
Q2 25
27.8%
Q1 25
-34.5%
Q4 24
28.8%
Q3 24
28.6%
Q2 24
26.8%
Q1 24
25.4%
Operating Margin
CLPR
CLPR
ZYME
ZYME
Q4 25
21.8%
Q3 25
23.6%
-80.1%
Q2 25
27.7%
-1.4%
Q1 25
-59.9%
-94.5%
Q4 24
28.1%
-71.6%
Q3 24
28.6%
-213.8%
Q2 24
26.8%
-222.9%
Q1 24
25.4%
-376.9%
Net Margin
CLPR
CLPR
ZYME
ZYME
Q4 25
-30.4%
Q3 25
-12.2%
-71.0%
Q2 25
-3.5%
4.8%
Q1 25
-89.1%
-83.5%
Q4 24
-2.9%
-75.8%
Q3 24
-2.9%
-186.6%
Q2 24
-4.7%
-195.8%
Q1 24
-7.5%
-315.6%
EPS (diluted)
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
$-0.26
Q2 25
$0.03
Q1 25
$-0.30
Q4 24
$-0.32
Q3 24
$-0.39
Q2 24
$-0.49
Q1 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLPR
CLPR
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$30.8M
$64.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-30.7M
$320.1M
Total Assets
$1.2B
$397.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLPR
CLPR
ZYME
ZYME
Q4 25
$30.8M
Q3 25
$26.1M
$64.8M
Q2 25
$32.0M
$98.3M
Q1 25
$21.3M
$76.2M
Q4 24
$19.9M
$66.1M
Q3 24
$18.6M
$122.4M
Q2 24
$20.3M
$71.0M
Q1 24
$21.9M
$114.8M
Total Debt
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
$1.3B
Q4 24
$1.3B
Q3 24
$1.3B
Q2 24
$1.2B
Q1 24
$1.2B
Stockholders' Equity
CLPR
CLPR
ZYME
ZYME
Q4 25
$-30.7M
Q3 25
$-25.0M
$320.1M
Q2 25
$-21.9M
$334.5M
Q1 25
$-20.1M
$325.0M
Q4 24
$-5.4M
$338.8M
Q3 24
$-3.6M
$367.0M
Q2 24
$-1.8M
$406.2M
Q1 24
$279.0K
$438.0M
Total Assets
CLPR
CLPR
ZYME
ZYME
Q4 25
$1.2B
Q3 25
$1.2B
$397.3M
Q2 25
$1.2B
$408.4M
Q1 25
$1.3B
$425.5M
Q4 24
$1.3B
$463.1M
Q3 24
$1.3B
$487.2M
Q2 24
$1.3B
$515.6M
Q1 24
$1.3B
$553.8M
Debt / Equity
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
4396.73×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLPR
CLPR
ZYME
ZYME
Operating Cash FlowLast quarter
$22.6M
$-31.4M
Free Cash FlowOCF − Capex
$-31.8M
FCF MarginFCF / Revenue
-115.2%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLPR
CLPR
ZYME
ZYME
Q4 25
$22.6M
Q3 25
$1.4M
$-31.4M
Q2 25
$8.4M
$12.1M
Q1 25
$6.7M
$-3.4M
Q4 24
$31.9M
$-41.5M
Q3 24
$6.3M
$-5.9M
Q2 24
$8.8M
$-25.0M
Q1 24
$6.3M
$-37.7M
Free Cash Flow
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
$-31.8M
Q2 25
$11.6M
Q1 25
$-4.6M
$-3.4M
Q4 24
$-37.9M
$-41.8M
Q3 24
$-6.8M
Q2 24
$-25.6M
Q1 24
$-14.7M
$-37.9M
FCF Margin
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
-115.2%
Q2 25
23.7%
Q1 25
-11.7%
-12.6%
Q4 24
-99.5%
-134.8%
Q3 24
-42.4%
Q2 24
-133.0%
Q1 24
-41.1%
-377.5%
Capex Intensity
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
1.5%
Q2 25
1.1%
Q1 25
28.6%
0.1%
Q4 24
183.3%
1.0%
Q3 24
5.6%
Q2 24
3.1%
Q1 24
58.6%
1.8%
Cash Conversion
CLPR
CLPR
ZYME
ZYME
Q4 25
Q3 25
Q2 25
5.21×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLPR
CLPR

Residential Segment$30.8M83%
Commercial Real Estate$6.2M17%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons